Get To Know Us

George Arida

George Arida

Chief Financial Officer (acting)

George Arida has 25 years’ experience as a venture capital fund manager, and previously worked in a range of technical, management, and executive positions in private and public companies. He currently serves as Chief Financial Officer for Clarametyx, and has extensive board and CFO/COO experience in early- and revenue-stage companies, including as board chair for ZyStor Therapeutics (acquired by BioMarin), Nerities (acquired by Kensey Nash, now DSM), Celleration (acquired by Alliqua Biomedical), Chromatin (acquired by S&W Seeds). George was previously CFO for BlueWillow Biologics and Capital Resource Advisors (acquired by RogersCasey), and has over a decade of prior experience in industry. He has a BS in Chemical Engineering from University of Illinois at Urbana-Champaign and an MBA from University of Chicago Booth School of Business.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.